文献速递消化系统肿瘤

曲妥珠单抗瑞泽替康治疗HER2表达晚期胃癌/胃食管结合部腺癌及结直肠癌:多中心开放标签I期试验

Trastuzumab Rezetecan in Human Epidermal Growth Factor Receptor 2-Expressing Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma and Colorectal Cancer: A Multicenter, Open-Label, Phase I Trial.
PubMed 文献 · J Clin Oncol · 2026-03-04

该I期试验评估新型HER2靶向抗体药物偶联物曲妥珠单抗瑞泽替康在HER2表达晚期胃癌/胃食管结合部腺癌和结直肠癌患者中的安全性与初步疗效。100例患者入组,剂量递增至8.0 mg/kg仅见1例剂量限制性毒性,≥3级治疗相关不良事件发生率为66.0%,因不良事件停药仅5.0%。在HER2阳性胃癌/胃食管结合部腺癌中客观缓解率45.0%,中位无进展生存期9.0个月,中位总生存期16.3个月;HER2阳性结直肠癌中客观缓解率40.5%,中位无进展生存期9.5个月,中位总生存期22.7个月。

要点

  • 曲妥珠单抗瑞泽替康在HER2表达晚期胃癌/胃食管结合部腺癌及结直肠癌中安全性可耐受。
  • HER2阳性胃癌/胃食管结合部腺癌客观缓解率45.0%,中位无进展生存期9.0个月。
  • HER2阳性结直肠癌客观缓解率40.5%,中位总生存期22.7个月。

核心结论

  • 曲妥珠单抗瑞泽替康在HER2表达晚期胃癌/胃食管结合部腺癌和结直肠癌中显示出可耐受的安全性和初步疗效。

研究设计与样本

  • 多中心、开放标签、I期试验,采用i3+3剂量递增方案,随后进行药代动力学扩展和临床扩展。
  • 2021年3月30日至2023年8月1日共入组100例患者,其中胃癌/胃食管结合部腺癌57例,结直肠癌43例。
  • 曲妥珠单抗瑞泽替康静脉给药,剂量为3.2、4.8、6.4和8.0 mg/kg,每3周一次。
  • 主要终点为剂量限制性毒性和安全性。

主要发现

  • 8.0 mg/kg剂量组发生1例剂量限制性毒性。
  • 66例(66.0%)患者报告≥3级治疗相关不良事件,仅5例(5.0%)因治疗相关不良事件停止治疗。
  • HER2阳性胃癌/胃食管结合部腺癌(n=40)客观缓解率45.0%,中位无进展生存期9.0个月(95% CI, 7.0至11.3),中位总生存期16.3个月(95% CI, 12.4至未达到)。
  • HER2免疫组化2+且原位杂交阴性胃癌/胃食管结合部腺癌(n=12)客观缓解率25.0%,中位无进展生存期12.2个月(95% CI, 2.8至14.0),中位总生存期未成熟。
  • HER2阳性结直肠癌(n=37)客观缓解率40.5%,中位无进展生存期9.5个月(95% CI, 7.3至11.2),中位总生存期22.7个月(95% CI, 17.5至未达到)。

临床怎么用

  • 对于HER2表达晚期胃癌/胃食管结合部腺癌和结直肠癌,曲妥珠单抗瑞泽替康可作为潜在治疗选择,但需进一步研究验证。

局限性

  • 为I期试验,样本量有限,疗效为初步结果。
  • HER2免疫组化2+且原位杂交阴性亚组样本量小(n=12),中位总生存期未成熟。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Antibody-drug conjugate (ADC) targeting human epidermal growth factor receptor 2 (HER2) could be a promising strategy for HER2-expressing gastric cancer or gastroesophageal junction adenocarcinoma (GC/GEJ) and colorectal cancer (CRC). We conducted a phase I trial to assess trastuzumab rezetecan, a novel HER2-targeted ADC, in HER2-expressing advanced GC/GEJ and CRC. METHODS: Patients with HER2-expressing advanced GC/GEJ and CRC whose disease progressed on and/or had no available/applicable standard treatment were enrolled. Patients were intravenously given trastuzumab rezetecan at 3.2, 4.8, 6.4, and 8.0 mg/kg (once every 3 weeks) in an i3+3 dose-escalation scheme, followed by pharmacokinetics expansion at selected doses and then clinical expansion. The primary end points were dose-limiting toxicity (DLT) and safety. RESULTS: Between March 30, 2021, and August 1, 2023, 100 patients were enrolled (57 with GC/GEJ and 43 with CRC). One DLT occurred in the 8.0 mg/kg dose cohort. Grade ≥3 treatment-related adverse events (TRAEs) were reported in 66 (66.0%) patients. Only 5 (5.0%) patients discontinued treatment because of TRAEs. In HER2-positive GC/GEJ (n = 40), trastuzumab rezetecan achieved an objective response rate (ORR) of 45.0%, a median progression-free survival (PFS) of 9.0 months (95% CI, 7.0 to 11.3), and a median overall survival (OS) of 16.3 months (95% CI, 12.4 to not reached [NR]). In GC/GEJ with HER2 immunohistochemical 2+ and in situ hybridization-negative (n = 12), trastuzumab rezetecan had an ORR of 25.0%, a median PFS of 12.2 months (95% CI, 2.8 to 14.0), and an immature median OS. In HER2-positive CRC (n = 37), trastuzumab rezetecan had an ORR of 40.5%, a median PFS of 9.5 months (95% CI, 7.3 to 11.2), and a median OS of 22.7 months (95% CI, 17.5 to NR). CONCLUSION: Trastuzumab rezetecan showed tolerable safety and preliminary efficacy in HER2-expressing advanced GC/GEJ and CRC.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Liu T, Luo S, Yuan X, et al. Trastuzumab Rezetecan in Human Epidermal Growth Factor Receptor 2-Expressing Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma and Colorectal Cancer: A Multicenter, Open-Label, Phase I Trial. J Clin Oncol. 2026. PMID: 41779980. doi:10.1200/JCO-25-00716

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。